A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)

PHASE3TerminatedINTERVENTIONAL

Enrollment

340

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

January 31, 2010

Study Completion Date

April 30, 2010

Conditions

Lymphoma, Non-Hodgkin's

Interventions

DRUG

Galiximab in combination with rituximab

Galiximab (500mg/m2 IV) in combination with Rituximab (375 mg/m2 IV), weekly x 4

DRUG

Rituximab in combination with placebo

Rituximab (375 mg/m2 IV) in combination with placebo, weekly x 4